

**ENANTA Pharmaceuticals, Inc.**

500 Arsenal Street  
Watertown, Massachusetts  
02472

Tel: 617.607.0800  
Fax: 617.607.0530  
www.enanta.com

For Immediate Release

**CONTACT:**

Paul Kidwell

617-296-3854

[paul\\_kidwell@hotmail.com](mailto:paul_kidwell@hotmail.com)

*News Release*

**Enanta Pharmaceuticals Appoints Yujiro Hata to  
Vice President of Business Development**



**WATERTOWN, Mass., October 23, 2002** -- Enanta Pharmaceuticals Inc.

(www.enanta.com), a leading drug discovery company that focuses on transforming existing drugs, natural products and biologically-active peptide leads into small molecules with improved pharmacological properties has named Yujiro Hata as Vice President, Business Development. In his new position, Mr. Hata will lead the Company's worldwide business development initiatives with the biopharmaceutical and pharmaceutical industries.

"Yujiro joins Enanta at an opportune time in our company's development, and we are excited to add such a brilliant and accomplished individual to our management team," said Spiros Jamas, President and CEO of Enanta Pharmaceuticals. "He has been successful in sourcing, negotiating and executing strategic alliances and licensing programs from pharmaceutical and biotechnology companies, and it's his level of commitment and ambition that he brings to this strategic role within Enanta."

Prior to joining Enanta Pharmaceuticals, Mr. Hata held the position of Senior Director of Corporate Development at Genome Therapeutics. He launched his business development career within the biotechnology industry at ImClone. Mr. Hata also was C.E.O. of eTechtransfer, developers of an enterprise-wide technology solution designed to streamline licensing within life sciences. In his career, he has been intimately involved in the business development of numerous drug discovery programs, including the partnering of Erbitux<sup>TM</sup>, the licensing of Phase III antibiotic Ramoplanin, and the management of an anti-infective alliance with Astra-Zeneca. Mr. Hata held consultant positions at McKinsey & Company and Merck & Co., Inc. where he worked on the launch strategy for the antibiotic, Invanz<sup>TM</sup>. He obtained his M.B.A. at The Wharton School of University of Pennsylvania as a Henry J. Kaiser Fellow, completed baccalaureate studies in Chemistry at Oxford University, and earned his B.A. in Chemistry at Colorado College.

- more -

**About Enanta**

Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its breakthrough chemistry technology - Drug Morphing™ and Peptide Morphing® -- to create new intellectual properties by transforming existing drugs, natural products and biologically active peptides into novel small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases.

# # #